hASCs were able to modulate Th17 responses by inhibiting the gene expression and/or secretion of IL-17, IL-21, and/or IL-6 by PHA-activated PBMCs isolated from RA vs. healthy donors, with more intense suppressive effects in the RA group due to their priming by the patients’ inflammation. This evidence concerns the gene IL17A and rheumatoid arthritis.